Literature DB >> 2925176

Monoclonality and polyclonality of plasma cells in Castleman's disease of the plasma cell variant.

T Radaszkiewicz1, M L Hansmann, K Lennert.   

Abstract

Castleman's disease of the plasma cell variant observed in 21 patients was investigated morphologically and by immunohistochemistry. The male to female ratio was 2.5:1. The age ranged from 18 to 71 years (mean age 47.6 years). Histologically, the lesions were characterized by numerous, evenly distributed germinal centres ranging from large hyperplastic to small hyaline-vascular types with moderate to extensive sheets of plasma cells in between. In all cases with generalized lymph node enlargement dilated sinuses could be found. Immunohistochemical studies demonstrated a polyclonal plasma cell population in 11 of 18 lesions. Seven lesions contained a monoclonal plasma cell population, five with IgG/lambda and two with IgA/lambda; clinically, two of these patients had generalized lymphadenopathy; in none could manifestation of a plasmacytoma be found outside the lymph node lesion; only two of the seven patients exhibited a paraproteinaemia (IgG/lambda and IgA/lambda, respectively) corresponding to the Ig type of the proliferated plasma cells. Six patients with polyclonal lesions had constitutional symptoms such as fever, anaemia, polyclonal hypergammaglobulinaemia; one of these six patients manifested symptoms consistent with a diagnosis of Takatsuki syndrome. The monoclonal plasma cell type of Castleman's disease did not progress to a generalized disease. This monoclonal variant may be a lymph nodebased type of benign monoclonal gammopathy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2925176     DOI: 10.1111/j.1365-2559.1989.tb02110.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

1.  Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression.

Authors:  Haipeng Shao; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Kieron Dunleavy; Wyndham H Wilson; Nelson Spector; Cristiane Milito; Jose Carlos Morais; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

Review 2.  [Diagnostic spectrum of reactive lymph node changes].

Authors:  S Hartmann; S Kriener; M L Hansmann
Journal:  Pathologe       Date:  2008-07       Impact factor: 1.011

Review 3.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

4.  Atypical immunoproliferative disorders: when of age?

Authors:  G Frizzera
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  Cellular localisation of HHV-8 in Castleman's disease: is there a link with lymph node vascularity?

Authors:  J O'Leary; M Kennedy; D Howells; I Silva; V Uhlmann; K Luttich; S Biddolph; S Lucas; J Russell; N Bermingham; M O'Donovan; M Ring; C Kenny; M Sweeney; O Sheils; C Martin; S Picton; K Gatter
Journal:  Mol Pathol       Date:  2000-04

Review 6.  Castleman's disease--a two compartment model of HHV8 infection.

Authors:  Klaus-Martin Schulte; Nadia Talat
Journal:  Nat Rev Clin Oncol       Date:  2010-07-06       Impact factor: 66.675

7.  Multicentric Castleman's disease in a patient with primary Sjögren's syndrome.

Authors:  A Tavoni; C Vitali; P Baglioni; R Gerli; G Marchetti; O Di Munno; S Bombardieri
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

Review 8.  Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis.

Authors:  Kwun Wah Wen; Blossom Damania
Journal:  Cancer Lett       Date:  2009-08-03       Impact factor: 8.679

9.  Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.

Authors:  M C Kinney; D S Hummell; P M Villiger; A Hourigan; L Rollins-Smith; A D Glick; A R Lawton
Journal:  J Clin Immunol       Date:  1994-11       Impact factor: 8.317

Review 10.  KSHV: pathways to tumorigenesis and persistent infection.

Authors:  Louise Giffin; Blossom Damania
Journal:  Adv Virus Res       Date:  2014       Impact factor: 9.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.